Ownership Summary
Quarter ending 30 Jun, 2026
Decoy Therapeutics Inc. (NASDAQ:DCOY) is held by 4 institutional investors per 13F filings through June 2026.
- They owned 0.8% of outstanding stock in June 2026, up from 0.3% the prior quarter.
- They increased total shares held in DCOY by 175.49% quarter over quarter, and investors in Decoy Therapeutics stayed flat from a year ago.
- Of these 4 holders, 2 added to their stakes in Decoy Therapeutics, 2 trimmed positions, and 0 made no changes.
- Altogether, these fund groups held 4.32K shares in DCOY by June 2026, up by 2.75K shares quarter on quarter, and with no net change year over year.
- VANGUARD CAPITAL MANAGEMENT LLC holds the largest position in DCOY at 4.03K shares as of June 30, 2026, or 0.76% of shares outstanding.
- Top purchasers of DCOY stock for the quarter ending June 2026 included VANGUARD CAPITAL MANAGEMENT LLC (4.03K), Caitong International Asset Management Co., Ltd (2).
- The largest sales of DCOY for the quarter ending June 2026 came from Tower Research Capital LLC (TRC) (765), UBS Group AG (521).
- Decoy Therapeutics's 4 largest shareholders as of June 2026 include VANGUARD CAPITAL MANAGEMENT LLC (4.03K), Tower Research Capital LLC (TRC) (256), UBS Group AG (25), Caitong International Asset Management Co., Ltd (2) per Business Quant data.